drugset / Trial / NCT00568503

Safety, Tolerability and Pharmacodynamics of QAX028 Compared to Open-label Tiotropium Bromide and Placebo in Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD) Patients.

NCT00568503

Phase 1 Completed 29 enrolled Novartis
RandomizedCrossoverDouble-blindTreatment

Summary

This will be a single dose Proof-of-Concept study in mild-to-moderate COPD patients. The study will investigate the safety and tolerability of QAX028 as well as the bronchodilatory effects of QAX028 compared to tiotropium and placebo in mild-to-moderate COPD patients.

Timeline

Start
2007-10
Primary completion
2008-02
Completion
2008-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator QAX028 Unknown
Comparator Tiotropium Other / unclassified